Proteins and Peptides
7 December 2017
Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes6 December 2017
Ozempic® (semaglutide) approved in the US4 December 2017
BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML4 December 2017
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia29 November 2017
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis29 November 2017
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)27 November 2017
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks17 November 2017
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology16 November 2017
Sobi™ – First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still’s Disease15 November 2017
FDA approves treatment for rare genetic enzyme disorder14 November 2017
Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand’s long-acting GLP-2 analog glepaglutide9 November 2017
Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-2008 November 2017
Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting2 November 2017
Biomarck Announces First Patients Treated in Phase 2 Clinical Trial of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)1 November 2017
Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients31 October 2017
NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect31 October 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl SyndromeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports